AssuredPartners Investment Advisors LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

AssuredPartners Investment Advisors LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 40,759 shares of the biopharmaceutical company’s stock, valued at approximately $1,081,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Down 1.4 %

Shares of Pfizer stock opened at $25.19 on Thursday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a market capitalization of $142.88 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The business’s fifty day moving average price is $26.12 and its two-hundred day moving average price is $26.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PFE shares. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.